INNATE PHARMA SA (IPHA) News
Filter IPHA News Items
IPHA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IPHA News Highlights
- IPHA's 30 day story count now stands at 4.
- Over the past 9 days, the trend for IPHA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about IPHA are SA, ASH and SNY.
Latest IPHA News From Around the Web
Below are the latest news stories about INNATE PHARMA SA that investors may wish to consider to help them evaluate IPHA as an investment opportunity.
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to SanofiMARSEILLE, France, December 19, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today that Sanofi has exercised its option to license a natural killer (NK) cell engager program in solid tumors from Innate’s ANKET® (Antibody-based NK Cell Engager Therapeutics) platform pursuant to the terms of the research collaboration and license agreement signed in December 2022. Following a research collaboration period, Sanofi will be responsible |
Innate Pharma Announces Leadership ChangeMARSEILLE, France, December 18, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that Mondher Mahjoubi has resigned from his position as Chief Executive Officer (CEO) and Chairman of the Executive Board of the Company, effective as of January 2024, to pursue a senior level opportunity at a large pharmaceutical company. |
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023MARSEILLE, France, December 11, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that the updated efficacy and safety results from an open-label, first-in-human, Phase 1/2 dose-escalation study of SAR443579 / IPH6101, an investigational CD123 targeting NKp46/CD16-based Natural Killer Cell Engager (NKCE) from a joint research collaboration between Innate Pharma and Sanofi were shared in a poster presentation at the American So |
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023MARSEILLE, France, December 10, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced positive final results from the Phase 2 TELLOMAK study in Sézary Syndrome (SS). The results were presented at the ASH 2023 Annual Meeting, in San Diego, California. |
Innate Pharma to Host Virtual KOL Event on LacutamabMARSEILLE, France, November 27, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that it will host a virtual KOL (Key Opinion Leader) event on lacutamab, a first-in-class anti-KIR3DL2 antibody currently in development for cutaneous T-cell lymphoma (CTCL) and peripheral T cell lymphoma (PTCL), on Tuesday, December 12, 2023, at 7:00AM PST (4:00PM CET). |
Innate Pharma S.A. (NASDAQ:IPHA) Q3 2023 Earnings Call TranscriptInnate Pharma S.A. (NASDAQ:IPHA) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Thank you for standing by, and welcome to the Innate Pharma Third Quarter 2023 Financial Results and Business Update. I would now like to welcome Henry Wheeler, VP, Investor Relations and Communications, to begin the call. Henry, over to you. Henry Wheeler: […] |
Innate Pharma Reports Third Quarter 2023 Financial Results and Business UpdateMARSEILLE, France, November 14, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced its revenues and cash position for the first nine months of 2023. |
Innate Pharma Announces Conference Call for Third Quarter 2023 Business UpdateMARSEILLE, France, November 07, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the Company will hold a conference call on Tuesday, November 14, 2023, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2023. |
Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023MARSEILLE, France, November 03, 2023--Innate Pharma announces new clinical data for lacutamab and SAR443579/IPH6101 at ASH 2023 |
Innate Pharma Announces Its Participation to Upcoming Investor ConferencesMARSEILLE, France, October 27, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below. |